Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
13767 | 752 | 25.8 | 60% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | THALASSEMIA MAJOR | Author keyword | 13 | 22% | 7% | 54 |
2 | MOL DIAGNOST BIOPHARMACEUT | Address | 7 | 67% | 1% | 6 |
3 | BETA THALASSEMIA MAJOR | Author keyword | 5 | 17% | 3% | 25 |
4 | BODY DISPROPORTION | Author keyword | 4 | 67% | 1% | 4 |
5 | BETA THALASSAEMIA MAJOR | Author keyword | 4 | 30% | 1% | 11 |
6 | THALASSAEMIA UNIT | Address | 4 | 24% | 2% | 14 |
7 | THALASSAEMIA MAJOR | Author keyword | 3 | 21% | 2% | 14 |
8 | AUXOENDOCRINOL UNIT | Address | 2 | 67% | 0% | 2 |
9 | CLIN BIOL DEV AGE | Address | 2 | 67% | 0% | 2 |
10 | PAEDIAT 29 | Address | 2 | 67% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | THALASSEMIA MAJOR | 13 | 22% | 7% | 54 | Search THALASSEMIA+MAJOR | Search THALASSEMIA+MAJOR |
2 | BETA THALASSEMIA MAJOR | 5 | 17% | 3% | 25 | Search BETA+THALASSEMIA+MAJOR | Search BETA+THALASSEMIA+MAJOR |
3 | BODY DISPROPORTION | 4 | 67% | 1% | 4 | Search BODY+DISPROPORTION | Search BODY+DISPROPORTION |
4 | BETA THALASSAEMIA MAJOR | 4 | 30% | 1% | 11 | Search BETA+THALASSAEMIA+MAJOR | Search BETA+THALASSAEMIA+MAJOR |
5 | THALASSAEMIA MAJOR | 3 | 21% | 2% | 14 | Search THALASSAEMIA+MAJOR | Search THALASSAEMIA+MAJOR |
6 | SHORT TRUNK | 2 | 67% | 0% | 2 | Search SHORT+TRUNK | Search SHORT+TRUNK |
7 | IRON LACTATE | 2 | 50% | 0% | 3 | Search IRON+LACTATE | Search IRON+LACTATE |
8 | ENDOCRINE COMPLICATIONS | 1 | 38% | 0% | 3 | Search ENDOCRINE+COMPLICATIONS | Search ENDOCRINE+COMPLICATIONS |
9 | MENSTRUATING WOMEN | 1 | 38% | 0% | 3 | Search MENSTRUATING+WOMEN | Search MENSTRUATING+WOMEN |
10 | BONE METABOLISM ETHANOL | 1 | 100% | 0% | 2 | Search BONE+METABOLISM+ETHANOL | Search BONE+METABOLISM+ETHANOL |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MAJOR | 11 | 100% | 1% | 6 |
2 | THALASSEMIA MAJOR | 8 | 11% | 10% | 72 |
3 | ENDOCRINE COMPLICATIONS | 7 | 42% | 2% | 13 |
4 | NEUROSECRETORY DYSFUNCTION | 6 | 40% | 2% | 12 |
5 | SHORT CHINESE CHILDREN | 6 | 100% | 1% | 4 |
6 | ENDOCRINE ABNORMALITIES | 5 | 35% | 1% | 11 |
7 | HOMOZYGOUS BETA THALASSEMIA | 5 | 18% | 3% | 23 |
8 | COOLEYS ANEMIA | 4 | 31% | 2% | 12 |
9 | HOMOZYGOUS THALASSEMIA | 3 | 100% | 0% | 3 |
10 | INDUCED BONE DYSPLASIA | 3 | 60% | 0% | 3 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Bone disease and skeletal complications in patients with beta thalassemia major | 2011 | 27 | 89 | 88% |
Growth and endocrine function in thalassemia major in childhood and adolescence | 2010 | 13 | 99 | 93% |
Iron homeostasis in osteoporosis and its clinical implications | 2012 | 19 | 63 | 46% |
Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials | 2014 | 2 | 39 | 38% |
Bisphosphonates in the treatment of thalassemia-associated osteoporosis | 2008 | 13 | 24 | 75% |
Growth, puberty and endocrine function in beta-thalassaemia major | 1997 | 45 | 42 | 83% |
New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia | 2004 | 70 | 97 | 44% |
The Spine in beta-Thalassemia Syndromes | 2012 | 4 | 67 | 70% |
The radiological appearances of thalassaemia | 2006 | 12 | 14 | 86% |
Complications of thalassemia major and their treatment | 2011 | 15 | 102 | 33% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MOL DIAGNOST BIOPHARMACEUT | 7 | 67% | 0.8% | 6 |
2 | THALASSAEMIA UNIT | 4 | 24% | 1.9% | 14 |
3 | AUXOENDOCRINOL UNIT | 2 | 67% | 0.3% | 2 |
4 | CLIN BIOL DEV AGE | 2 | 67% | 0.3% | 2 |
5 | PAEDIAT 29 | 2 | 67% | 0.3% | 2 |
6 | HAEMATOL WOMENS HLTH | 1 | 100% | 0.3% | 2 |
7 | MED THER Y UNIT | 1 | 50% | 0.3% | 2 |
8 | PEDIAT ADOLESCENT OUTPATIENT CLIN | 1 | 50% | 0.3% | 2 |
9 | PEDIAT MED ADOLESCENZA | 1 | 100% | 0.3% | 2 |
10 | S BAMBINO HOSP | 1 | 100% | 0.3% | 2 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000256835 | DEFERASIROX//IRON OVERLOAD//DEFERIPRONE |
2 | 0.0000148476 | NUTR GROWTH//PROPHYLACTIC TRANSFUSION//NUCLEO ACOES PESQUISA OIO DIAGNOST NUPAD |
3 | 0.0000133411 | INT TRANSPLANTAT THALASSEMIA SICKLE CELL AN//MEDITERRANEAN HEMATOL//TR IANTO MIDOLLO OSSEO MURAGLIA |
4 | 0.0000123175 | AHSP//ALPHA HEMOGLOBIN STABILIZING PROTEIN AHSP//ALPHA HEMOGLOBIN STABILIZING PROTEIN |
5 | 0.0000073911 | EXTRAMEDULLARY HEMATOPOIESIS//EXTRAMEDULLARY HAEMATOPOIESIS//EXTRAMEDULLARY HAEMOPOIESIS |
6 | 0.0000071169 | FERRIC SORBITOL CITRATE//FERRIC SORBITOL CITRATE FSC//NF KAPPA B EXPRESSION ACTIVATION |
7 | 0.0000063116 | IRON POISONING//IRON OVERDOSE//IRON INTOXICATION |
8 | 0.0000058069 | EIJKMAN IMMUNOL INFECT DIS//MALATTIE METAB FEGATO//NUCLEAR MICROSCOPY |
9 | 0.0000040342 | HEPATIC OSTEODYSTROPHY//LIMB REGENERAT//UNITE INSERM U658 |
10 | 0.0000037500 | SPZ RHEUMATOL//MUSCLE BONE UNIT//PHYSIOL BIOMECAN PERFORMANCE MOTRICE |